ArticleAmerican journal of cancer research2023
Galectin-8 alters immune microenvironment and promotes tumor progression.
Article in American journal of cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 7 citations in OpenAlex.
- The Galectin Family in Colorectal Cancer: Integrating Molecular Mechanisms with Diagnostic, Prognostic, and Therapeutic Perspectives.Biomedicines · 2026Review
- Galectins at the crossroads of tumor immunity, metabolism, and metastasis: mechanisms, therapeutic resistance, and translational opportunities.Frontiers in immunology · 2026Review
- Integration of eQTL and GEO Datasets to Identify Genes Associated with Breast Ductal Carcinoma In Situ.Current issues in molecular biology · 2025Article
- Global Thyroid Cancer Patterns and Predictive Analytics: Integrating Machine Learning for Advanced Diagnostic Modelling.Journal of cellular and molecular medicine · 2025Article
- Multifaceted roles of Galectins: from carbohydrate binding to targeted cancer therapy.Biomarker research · 2025Review
- Cross-Species Insights from Single-Nucleus Sequencing Highlight Aging-Related Hippocampal Features in Tree Shrew.Molecular biology and evolution · 2025Article
- CD98hc, a novel of galectin-8 receptor, binds to galectin-8 in an N-glycosylation-dependent manner.Acta biochimica et biophysica Sinica · 2025Article
- Exploring the Potential Causal Relationship of Galectin Levels and Gynecologic Cancers: A Two-Sample Mendelian Randomization Study.International journal of women's health · 2025Article
- Expression of Intracellular Galectin-8 and -9 in Endometrial Cancer.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Galectin-8 (Gal-8), encoded by LGALS8 gene, is a unique member of the Galectin family with diverse biological functions, including tumor-modulating capabilities. Recently, evidence has accumulated supporting an essential role for Gal-8 in regulating innate and adaptive immunity, with high expression in tumors and other immune dysregulation diseases. This study reveals the role of Gal-8-induced tumor immunosuppression by analyzing animal models and clinical data of tumor-infiltrating cells. In Gal-8 expressing tumor, we found that suppressive immune cells, including Tregs and MDSCs, expanded while CD8+ cells decreased, providing direct evidence that Gal-8 regulates the tumor immune microenvironment. In addition, we not only analyzed the expression of Gal-8 in clinical samples of breast and colorectal cancer but also classified the tissue expression patterns. Further analysis revealed that Gal-8 correlates with lymph node metastasis and immunophenotyping. Consistent with animal experiments, our analysis of LGALS8 gene expression showed its negative association with infiltrated active CD8+ T cells and immune stimulatory modulators in cancers. Our study identified the potential prognostic and therapeutic value of Gal-8, and further research on developing corresponding targeted therapeutic strategies is awaited.
Indexed as
Identifiers
37424827PMC10326578W4383710098What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.